VRCA - Verrica Pharmaceuticals Inc.
IEX Last Trade
0.6719
0.017 2.500%
Share volume: 18,071
Last Updated: Fri 27 Dec 2024 08:25:38 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.66
0.02
2.56%
Fundamental analysis
30%
Profitability
25%
Dept financing
25%
Liquidity
75%
Performance
25%
Performance
5 Days
-7.79%
1 Month
-47.69%
3 Months
-61.62%
6 Months
-91.02%
1 Year
-90.93%
2 Year
-73.74%
Key data
Stock price
$0.67
DAY RANGE
$0.63 - $0.66
52 WEEK RANGE
$0.70 - $11.41
52 WEEK CHANGE
-$91.14
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Ted White
Region: US
Website: verrica.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: verrica.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Verrica Pharmaceuticals Inc. develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; VP-103 for treating plantar warts.
Recent news